http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2203274-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
filingDate 1995-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd353bc9b009350567061c9d0ce4b4a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f74c38d31c347507ef0add5eb5db8bf5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_622e2b26049c4235b63c4a1dfdee08b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d1c06ae170025af34b07100a93039dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f0794995559a2efe556150433665b1f
publicationDate 1996-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2203274-A1
titleOfInvention Apolipoprotein-b synthesis inhibitors
abstract The present invention provides novel compounds of formula (I), the N-oxides, the stereochemically isomeric forms thereof, and the pharmaceutically acceptable acid addition salts thereof, wherein A and B taken together form a bivalent radical of formula: -N=CH- (a), -CH=N- (b), -CH2-CH2- (c), -CH=CH-(d), -C(=O)-CH2- (e), -CH2-C(=O)- (f); R1 is hydrogen, C1-6alkyl, or halo; R2 is hydrogen or halo; R3 is hydrogen; C1-8alkyl; C3-6cycloalkyl or C1-8 alkyl substituted with hydroxy, oxo, C3-6cycloalkyl or aryl. Het is five- or six membered optionally substituted heterocyclic ring. The use as a medicine, especially as a lipid lowering agent is disclosed as well as pharmaceutical compositions and processes for preparing compounds and compositions.
priorityDate 1994-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457623688
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID338
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID238055
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID494004
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID54225
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID457655803

Total number of triples: 35.